Description_x000D_ Application_x000D_ Tideglusib has been used:_x000D_ • as a reference compound in ADP-GloTM Kinase assay_x000D_ • as an allosteric inhibitor of GSK-3β to study its effects on myocardial remodeling and angiogenesis_x000D_ • as a differentiation agent (specifically a glycogen synthase kinase (GSK)-3β inhibitor) to convert fibroblast cells into octamer-binding transcription factor-4 (OCT4)+ and vascular endothelial growth factor receptor-2 (VEGFR-2/fetal liver kinase-1 (FLK1)+ cells_x000D_ Packaging_x000D_ 10, 50 mg in glass bottle_x000D_ Biochem/physiol Actions_x000D_ Tideglusib, also known as NP031112 or NP-12, is a potent non ATP-competitive inhibitor of glycogen synthase kinase-3 (GSK3), an important kinase studied in stem cell research and neurodegenerative diseases. It is currently in clinical trials for Alzheimer′s disease and Progressive Supranuclear Palsy (PSP). Tideglusib reduces phosphorylation of the tau protein and the accumulation of amyloid plaques, reduces hippocampal and entorhinal cortex neuron loss and improves spatial memory deficits. It has also shown neuroprotective and anti-inflammatory activity in a variety of animal models._x000D_ Features and Benefits_x000D_ This compound is featured on the GSK-3 page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.